Cargando…

Novel Treatment Strategies for Glioblastoma

Glioblastoma (GBM) is the most common primary central nervous system tumor in adults. It is a highly invasive disease, making it difficult to achieve a complete surgical resection, resulting in poor prognosis with a median survival of 12–15 months after diagnosis, and less than 5% of patients surviv...

Descripción completa

Detalles Bibliográficos
Autor principal: Stylli, Stanley S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599818/
https://www.ncbi.nlm.nih.gov/pubmed/33049911
http://dx.doi.org/10.3390/cancers12102883
_version_ 1783602974895898624
author Stylli, Stanley S.
author_facet Stylli, Stanley S.
author_sort Stylli, Stanley S.
collection PubMed
description Glioblastoma (GBM) is the most common primary central nervous system tumor in adults. It is a highly invasive disease, making it difficult to achieve a complete surgical resection, resulting in poor prognosis with a median survival of 12–15 months after diagnosis, and less than 5% of patients survive more than 5 years. Surgical, instrument technology, diagnostic and radio/chemotherapeutic strategies have slowly evolved over time, but this has not translated into significant increases in patient survival. The current standard of care for GBM patients involving surgery, radiotherapy, and concomitant chemotherapy temozolomide (known as the Stupp protocol), has only provided a modest increase of 2.5 months in median survival, since the landmark publication in 2005. There has been considerable effort in recent years to increase our knowledge of the molecular landscape of GBM through advances in technology such as next-generation sequencing, which has led to the stratification of the disease into several genetic subtypes. Current treatments are far from satisfactory, and studies investigating acquired/inherent resistance to current therapies, restricted drug delivery, inter/intra-tumoral heterogeneity, drug repurposing and a tumor immune-evasive environment have been the focus of intense research over recent years. While the clinical advancement of GBM therapeutics has seen limited progression compared to other cancers, developments in novel treatment strategies that are being investigated are displaying encouraging signs for combating this disease. This aim of this editorial is to provide a brief overview of a select number of these novel therapeutic approaches.
format Online
Article
Text
id pubmed-7599818
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75998182020-11-01 Novel Treatment Strategies for Glioblastoma Stylli, Stanley S. Cancers (Basel) Editorial Glioblastoma (GBM) is the most common primary central nervous system tumor in adults. It is a highly invasive disease, making it difficult to achieve a complete surgical resection, resulting in poor prognosis with a median survival of 12–15 months after diagnosis, and less than 5% of patients survive more than 5 years. Surgical, instrument technology, diagnostic and radio/chemotherapeutic strategies have slowly evolved over time, but this has not translated into significant increases in patient survival. The current standard of care for GBM patients involving surgery, radiotherapy, and concomitant chemotherapy temozolomide (known as the Stupp protocol), has only provided a modest increase of 2.5 months in median survival, since the landmark publication in 2005. There has been considerable effort in recent years to increase our knowledge of the molecular landscape of GBM through advances in technology such as next-generation sequencing, which has led to the stratification of the disease into several genetic subtypes. Current treatments are far from satisfactory, and studies investigating acquired/inherent resistance to current therapies, restricted drug delivery, inter/intra-tumoral heterogeneity, drug repurposing and a tumor immune-evasive environment have been the focus of intense research over recent years. While the clinical advancement of GBM therapeutics has seen limited progression compared to other cancers, developments in novel treatment strategies that are being investigated are displaying encouraging signs for combating this disease. This aim of this editorial is to provide a brief overview of a select number of these novel therapeutic approaches. MDPI 2020-10-08 /pmc/articles/PMC7599818/ /pubmed/33049911 http://dx.doi.org/10.3390/cancers12102883 Text en © 2020 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Editorial
Stylli, Stanley S.
Novel Treatment Strategies for Glioblastoma
title Novel Treatment Strategies for Glioblastoma
title_full Novel Treatment Strategies for Glioblastoma
title_fullStr Novel Treatment Strategies for Glioblastoma
title_full_unstemmed Novel Treatment Strategies for Glioblastoma
title_short Novel Treatment Strategies for Glioblastoma
title_sort novel treatment strategies for glioblastoma
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599818/
https://www.ncbi.nlm.nih.gov/pubmed/33049911
http://dx.doi.org/10.3390/cancers12102883
work_keys_str_mv AT styllistanleys noveltreatmentstrategiesforglioblastoma